The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates.
暂无分享,去创建一个
G. Drusano | D. Benjamin | T. Walsh | J. Keirns | A. Groll | W. Hope | D. Buell | J. Bacher | D. Mickiene | Amy M. Kelaher | Johanna E. Hughes | Margaret P. Cotton | R. Petraitiene | G. Heresi | V. Petraitis | Amy M Kelaher | R. Petraitienė
[1] G. Drusano,et al. Population pharmacokinetics of micafungin in adult patients. , 2008, Diagnostic microbiology and infectious disease.
[2] B. Keevil,et al. Optimization of the Dosage of Flucytosine in Combination with Amphotericin B for Disseminated Candidiasis: a Pharmacodynamic Rationale for Reduced Dosing , 2007, Antimicrobial Agents and Chemotherapy.
[3] A. Mejias,et al. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. , 2007, The Pediatric infectious disease journal.
[4] B. Alexander,et al. Neonatal Candida meningitis: significance of cerebrospinal fluid parameters and blood cultures , 2007, Journal of Perinatology.
[5] G. Kearns,et al. The Pharmacokinetics and Safety of Micafungin, a Novel Echinocandin, in Premature Infants , 2006, The Pediatric infectious disease journal.
[6] Yaming Su,et al. Drug delivery across the blood–brain barrier: why is it difficult? how to measure and improve it? , 2006, Expert opinion on drug delivery.
[7] J. Sobel,et al. Micafungin: a new echinocandin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] William Oh,et al. Neonatal Candidiasis Among Extremely Low Birth Weight Infants: Risk Factors, Mortality Rates, and Neurodevelopmental Outcomes at 18 to 22 Months , 2006, Pediatrics.
[9] G. Drusano,et al. Pharmacodynamics of Caspofungin in a Murine Model of Systemic Candidiasis: Importance of Persistence of Caspofungin in Tissues to Understanding Drug Activity , 2005, Antimicrobial Agents and Chemotherapy.
[10] G. Natarajan,et al. Experience with Caspofungin in the Treatment of Persistent Fungemia in Neonates , 2005, Journal of Perinatology.
[11] T. Walsh,et al. Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. , 2005, Medical mycology.
[12] D. Andes,et al. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] T. Walsh,et al. Caspofungin Therapy of Neonates With Invasive Candidiasis , 2004, The Pediatric infectious disease journal.
[14] D. Denning. Echinocandin antifungal drugs , 2003, The Lancet.
[15] T. Walsh,et al. Comparative Antifungal Activities and Plasma Pharmacokinetics of Micafungin (FK463) against Disseminated Candidiasis and Invasive Pulmonary Aspergillosis in Persistently Neutropenic Rabbits , 2002, Antimicrobial Agents and Chemotherapy.
[16] Roger W. Jelliffe,et al. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) population models , 2001, Proceedings 14th IEEE Symposium on Computer-Based Medical Systems. CBMS 2001.
[17] D. Noyola,et al. Candidal meningitis in neonates: a 10-year review. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] S. Piscitelli,et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. , 2000, The Journal of infectious diseases.
[19] S. Richardson,et al. Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome , 2000, The Pediatric infectious disease journal.
[20] F. Aweeka,et al. The penetration of anti-infectives into the central nervous system. , 1999, Neurologic clinics.
[21] G. Mccracken,et al. Antibiotic pharmacodynamics in cerebrospinal fluid. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] Andrew N. Rowan. Guide for the Care and Use of Laboratory Animals , 1996 .
[23] Klaus D. Tönnies,et al. Edge detection using the local fractal dimension , 1994, Proceedings of IEEE Symposium on Computer-Based Medical Systems (CBMS).
[24] K. Olsen,et al. Effects of antifungal therapy on inflammation, sterilization, and histology in experimental Candida albicans meningitis , 1994, Antimicrobial Agents and Chemotherapy.
[25] K. Olsen,et al. Characteristics of experimental Candida albicans infection of the central nervous system in rabbits. , 1991, The Journal of infectious diseases.
[26] T. Walsh,et al. Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. , 1988, Laboratory animal science.
[27] J. Perfect,et al. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. , 1985, The Journal of antimicrobial chemotherapy.
[28] S. Piscitelli,et al. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. , 1998, Advances in pharmacology.
[29] G. Lopez-Berestein,et al. Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. , 1984, Cancer drug delivery.
[30] G. Mccracken,et al. Pharmacology and efficacy of vancomycin for staphylococcal infections in children. , 1981, Reviews of infectious diseases.